Dopamine-dependent motor learning insight into levodopa's long-duration response

Annals of Neurology

Volumn 67, Issue 5, 2010, Pages 639-647

  Beeler, Jeff A ^a   Cao, Zhen Fang Huang ^a   Kheirbek, Mazen A ^a,b   Ding, Yunmin ^a   Koranda, Jessica ^a   Murakami, Mari ^a   Kang, Un Jung ^a   Zhuang, Xiaoxi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENSERAZIDE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA;

ANIMAL EXPERIMENT; APHAKIA; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; GENE; LEARNING; MOTOR ACTIVITY; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PARKINSON DISEASE; PITX3 GENE; PRIORITY JOURNAL; ROTAROD TEST; TASK PERFORMANCE;

ANIMALS; BEHAVIOR, ANIMAL; BENZAZEPINES; DOPAMINE; DOPAMINE AGENTS; HOMEODOMAIN PROTEINS; LEARNING; LEVODOPA; MICE; MICE, KNOCKOUT; MOTOR SKILLS; MOVEMENT DISORDERS; REACTION TIME; ROTAROD PERFORMANCE TEST; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 77951745860     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21947     Document Type: Article

References (40)

1. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968;5:107-110.
2. Sedelis M, Schwarting RK, Huston JP. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001;125:109-125. (Pubitemid 33000449)
3. Zhou QY, Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 1995;83:1197-1209.
4. Ogura T, Ogata M, Akita H, et al. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease. Neurosci Res 2005;51:299-308. (Pubitemid 40248553)
5. Packard MG, Knowlton BJ. Learning and memory functions of the basal ganglia. Annu Rev Neurosci 2002;25:563-593. (Pubitemid 34748029)
6. Miyachi S, Hikosaka O, Lu X. Differential activation of monkey striatal neurons in the early and late stages of procedural learning. Exp Brain Res 2002;146:122-126. (Pubitemid 34985335)
7. Reynolds JN, Wickens JR. Substantia nigra dopamine regulates synaptic plasticity and membrane potential fluctuations in the rat neostriatum, in vivo. Neuroscience 2000;99:199-203.
8. Yin HH, Mulcare SP, Hilario MR, et al. Dynamic reorganization of striatal circuits during the acquisition and consolidation of a skill. Nat Neurosci 2009;12:333-341.
9. Dang MT, Yokoi F, Yin HH, et al. Disrupted motor learning and long-term synaptic plasticity in mice lacking NMDAR1 in the striatum. Proc Natl Acad Sci U S A 2006;103:15254-15259. (Pubitemid 44583197)
10. Hwang DY, Ardayfio P, Kang UJ, et al. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res 2003;114:123-131. (Pubitemid 36773553)
11. Smits SM, Mathon DS, Burbach JP, et al. Molecular and cellular alterations in the Pitx3-deficient midbrain dopaminergic system. Mol Cell Neurosci 2005;30:352-363.
12. Ardayfio P, Moon J, Leung KK, et al. Impaired learning and memory in Pitx3 deficient aphakia mice: a genetic model for striatum-dependent cognitive symptoms in Parkinson's disease. Neurobiol Dis 2008;31:406-412.
13. Beeler JA, Cao ZF, Kheirbek MA, Zhuang X. Loss of cocaine locomotor response in Pitx3-deficient mice lacking a nigrostriatal pathway. Neuropsychopharmacology 2009;34:1149-1161.
14. Ding Y, Restrepo J, Won L, et al. Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. Neurobiol Dis 2007;27:11-23. (Pubitemid 46921471)
15. Hwang DY, Fleming SM, Ardayfio P, et al. 3,4-Dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J Neurosci 2005;25:2132-2137. (Pubitemid 40289418)
16. Singh B, Wilson JH, Vasavada HH, et al. Motor deficits and altered striatal gene expression in aphakia (ak) mice. Brain Res 2007;1185:283-292. (Pubitemid 350166296)
17. Kas MJ, van der Linden AJ, Oppelaar H, et al. Phenotypic segregation of aphakia and Pitx3-null mutants reveals that Pitx3 deficiency increases consolidation of specific movement components. Behav Brain Res 2008;186:208-214. (Pubitemid 350122764)
18. Nunes I, Tovmasian LT, Silva RM, et al. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci U S A 2003;100:4245-4250. (Pubitemid 36418188)
19. van den Munckhof P, Luk KC, Ste-Marie L, et al. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 2003;130:2535-2542. (Pubitemid 36722403)
20. Brooks DJ. The early diagnosis of Parkinson's disease. Ann Neurol 1998;44:S10-S18.
21. Chang JW, Wachtel SR, Young D, Kang UJ. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 1999;88:617-628. (Pubitemid 28480020)
22. Bergman H, Feingold A, Nini A, et al. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci 1998;21:32-38. (Pubitemid 128766376)
23. Wiecki TV, Riedinger K, von Ameln-Mayerhofer A, et al. A neurocomputational account of catalepsy sensitization induced by D2 receptor blockade in rats: context dependency, extinction, and renewal. Psychopharmacology (Berl) 2009;204:265-277.
24. Shen W, Flajolet M, Greengard P, Surmeier DJ. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008;321:848-851.
25. Muenter MD, Tyce GM. L-Dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-239.
26. Tedroff J, Pedersen M, Aquilonius SM, et al. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology 1996;46:1430-1436. (Pubitemid 126425743)
27. Nutt JG, Carter JH, Woodward WR. Long-duration response to levodopa. Neurology 1995;45:1613-1616.
28. Zappia M, Colao R, Montesanti R, et al. Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease. Ann Neurol 1997;42:245-248. (Pubitemid 27340471)
29. Metman LV, Locatelli ER, Bravi D, et al. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48:369-372. (Pubitemid 27087605)
30. Siegert RJ, Taylor KD, Weatherall M, Abernethy DA. Is implicit sequence learning impaired in Parkinson's disease? A metaanalysis. Neuropsychology 2006;20:490-495. (Pubitemid 44199168)
31. Ghilardi MF, Eidelberg D, Silvestri G, Ghez C. The differential effect of PD and normal aging on early explicit sequence learning. Neurology 2003;60:1313-1319. (Pubitemid 36460988)
32. Jackson GM, Jackson SR, Harrison J, et al. Serial reaction time learning and Parkinson's disease: evidence for a procedural learning deficit. Neuropsychologia 1995;33:577-593.
33. Krebs HI, Hogan N, Hening W, et al. Procedural motor learning in Parkinson's disease. Exp Brain Res 2001;141:425-437. (Pubitemid 33145101)
34. Behrman AL, Cauraugh JH, Light KE. Practice as an intervention to improve speeded motor performance and motor learning in Parkinson's disease. J Neurol Sci 2000;174:127-136.
35. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 1989;46:1052-1060. (Pubitemid 19246292)
36. Nutt JG, Carter JH, Van Houten L, Woodward WR. Short-and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol 1997;42:349-355. (Pubitemid 27391118)
37. Madden DL, Morris JG, Graham SJ, et al. The long duration response to levodopa in Parkinson's disease. J Clin Neurosci 1995;2:48-54.
38. Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002;51:686-693. (Pubitemid 34568846)
39. Quattrone A, Zappia M, Aguglia U, et al. The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann Neurol 1995;38:389-395.
40. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.